Cognition Therapeutics, Inc. CGTX

CGTX Company Overview

Cognition Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing small-molecule therapeutics for neurodegenerative and central nervous system disorders. The company’s research is centered on targeting the sigma-2 receptor complex, which it believes plays a role in synaptic function, protein trafficking, and cellular processes associated with diseases such as Alzheimer’s disease, dementia with Lewy bodies, and other neurodegenerative conditions. Cognition Therapeutics operates within the biotechnology and pharmaceutical research industries and generates no material commercial product revenue as of publicly available filings, with operations primarily funded through equity offerings, grants, and research-related financing activities.

The company’s primary asset is its proprietary portfolio of sigma-2 receptor modulators, led by CT1812, an investigational oral therapy being evaluated in clinical trials for Alzheimer’s disease and related disorders. Cognition Therapeutics positions itself around a differentiated mechanism of action intended to displace toxic oligomers from neuronal receptors, which the company believes could preserve synaptic function. The company was founded in 2007 and evolved from an early-stage neuroscience research enterprise into a publicly traded biotechnology company listed on Nasdaq under the ticker CGTX. Its development strategy has increasingly focused on advancing late-stage clinical evaluation and expanding applications of its platform technology across multiple neurodegenerative indications.